Dermata Therapeutics, Inc. has recently seen a notable investment from Bigger Capital Fund LP and District 2 Capital Fund LP, as disclosed in a Schedule 13G filing. This filing, dated November 2, 2026, reveals that these entities collectively own a significant portion of the company’s common stock. The investment is expected to enhance Dermata's position within the competitive landscape of the pharmaceutical preparations industry.

Dermata Therapeutics, based in San Diego, California, operates in the pharmaceutical preparations sector, specifically focusing on developing innovative therapies for dermatological conditions. The company trades on the Nasdaq under the ticker symbol DRMA. As an emerging growth company, Dermata is actively involved in advancing its product pipeline and expanding its market presence.

The Schedule 13G filing indicates that Bigger Capital Fund beneficially owns 242,832 shares of Dermata's common stock, representing approximately 4.90% of the outstanding shares. Additionally, District 2 Capital Fund holds 171,232 shares, accounting for about 3.46% of the total shares. The filing also notes that Michael Bigger, as a managing member of both funds, may be deemed to beneficially own a combined total of approximately 8.36% of Dermata's common stock.

Furthermore, the filing highlights that these investments do not include shares issuable upon the exercise of various warrants, which are subject to shareholder approval and limitations. For instance, Bigger Capital has warrants that could potentially increase its stake significantly, depending on future decisions by shareholders.

This investment may have several implications for Dermata Therapeutics and the broader pharmaceutical preparations industry. With increased backing from these investment firms, Dermata could gain access to additional resources necessary for research and development, potentially accelerating its product development timelines. This could also signal to other investors that Dermata is a company worth watching, possibly leading to further investments in the future.

The filing does not specify the next steps for Dermata or the investors involved, but the increased ownership stakes may prompt further disclosures or actions as the company continues to navigate its growth strategy.